- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04698980
Evaluation of the STANDARD G6PD Rapid Test for Assaying the Enzymatic Activity of G6PD in French Guiana (G6PD facile)
In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatments against Plasmodium vivax malaria are: nivaquine for 3 days against circulating blood parasites and primaquine for 14 days against parasites dormant in the liver. Primaquine can cause iatrogenic hemolytic anemias in patients with favism, i.e. G6PD deficiency. This anemia can be severe enough to cause the death of the deficient patient. Thus, the WHO and HCSP recommendations indicate that a quantitative assay of the activity of this enzyme should be carried out before its prescription. This deficiency is a recessive inherited disease linked to the X chromosome characterized by more or less low levels of enzymatic activity which depends on the genotype of the patients but not only because the phenotype depends on the level of activation of the X chromosome for each cell.
Currently, obtaining a G6PD assay in French Guiana is a long process since it is done in mainland France and the pre-analytical conditions are quite demanding. Thus, in areas of transmission of P. vivax, patients usually have a bout of revival before being prescribed primaquine. This period includes: dosing G6PD at a distance from access, obtaining the result and then the nominal ATU to finally obtain and deliver the primaquine.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a interventional,prospective, multicenter, cross-sectional and comparative study.
To achieve this study, the following will be done:
- Selection of subjects according to their G6PD activity from the list of participants previously included in the ELIMALAR Palustop study and from known LHUPM patients in Cayenne following a request for a G6PD dosage, whether or not related to malaria.
- Collection of clinical data from participants (sex, age, ethnicity of parents and grandparents).
- Collection of blood samples from subjects showing G6PD activity of the following three categories "severe deficiency", "intermediate", "normal".
- Determination of G6PD activity by the "STANDARD G6PD" technique from SD BIOSENSOR versus the reference enzymatic method
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lise Musset, PharmD
- Phone Number: +335 94 29 68 40
- Email: lmusset@pasteur-cayenne.fr
Study Locations
-
-
-
Cayenne, French Guiana
- Recruiting
- Institut Pasteur de la Guyane
-
Contact:
- Lise Musset
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- People with a known level of G6PD activity.
- People or their legal representatives who have received information on the research and have signed a written consent to participate in the study
- People aged over 18 for the "intermediate" and "normal" categories,
- People aged two years and over for the "severe deficit" category.
Exclusion Criteria:
- People with an unknown level of G6PD activity,
- People or their legal representatives who refused to participate in the study,
- People aged under 18 for the intermediate and normal categories,
- Children under 2 years old for the "severe deficit" category,
- People with a hemoglobin level below 11g / dL for men and 10g / dL for women and children.
- People who received a transfusion less than 4 months before the proposal to participate in the G6PD study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: participants selected according to their G6PD activity
|
For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the STANDARD G6PD test
Time Frame: 3 years
|
The sensitivity and specificity will be calculated for the detection of severe deficits in G6PD activity (<30%), intermediate activities (30-80%) and normal activities (> 80%) of the STANDARD G6PD test vs the reference enzymatic method
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Verification of the analysis method by the STANDARD G6PD test several times
Time Frame: 3 years
|
Measurement of the G6PD activity will be done to assess the repeatability, accuracy or trueness of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation.
|
3 years
|
Verification of the analysis method by the STANDARD G6PD test by different operator
Time Frame: 3 years
|
Measurement of the G6PD activity will be done to assess the inter-operator variability, of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation.
|
3 years
|
Verification of the analysis method by the STANDARD G6PD test in different conditions
Time Frame: 3 years
|
Measurement of the G6PD activity will be done to assess the reproducibility, robustness and measurement interval of the STANDARD G6PD test according to the recommendations of standard NF EN ISO 15189: 2012 for accreditation.
|
3 years
|
sequencing of the coding regions of the G6PD gene of 150 individuals
Time Frame: 3 years
|
Analysis of the genotype of the G6PD gene and comparison to the phenotype
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lise Musset, PharmD, Institut Pasteur de la Guyane, head of Parasitology laboratory
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Infections
- Hematologic Diseases
- Genetic Diseases, Inborn
- Vector Borne Diseases
- Anemia
- Parasitic Diseases
- Protozoan Infections
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Malaria
- Glucosephosphate Dehydrogenase Deficiency
Other Study ID Numbers
- 2019-015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paludism
-
Institute of Tropical Medicine, BelgiumTerminatedCovid19 | PaludismCongo, The Democratic Republic of the
Clinical Trials on blood samples (venous and capillary at the fingertip)
-
ICF Macro, Inc.United States Agency for International Development (USAID); Uganda Bureau of...Completed
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisUnknown
-
LumiraDx UK LimitedCompletedAnticoagulants and Bleeding DisordersGermany
-
Assiut UniversityCompleted
-
Izmir Bakircay UniversityEge UniversityCompletedBlood Glucose, LowTurkey
-
Centre Hospitalier Universitaire DijonRecruiting
-
Istanbul University - Cerrahpasa (IUC)Recruiting
-
Institut Claudius RegaudRecruiting
-
Hôpital Necker-Enfants MaladesUniversity Hospital, Strasbourg, France; Poitiers University Hospital; University... and other collaboratorsUnknownShock, Septic | Shock, HemorrhagicFrance